AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Trial Of SCI-110 For Tourette Syndrome July 15, 2026 — 10:47 am EDT Written by RTTNews.com for RTTNews -> (RTTNews) - SciSparc Ltd. (SPRC) announced that its subsidiary, NeuroThera Labs Inc. (NTLX.V), a clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders, initiated its Phase IIb clinical trial site for SCI-110, its investigational candidate for the treatment of Tourette Syndrome (TS) in adults. Tourette syndrome (TS) is a neurological disorder characterized by repeated, involuntary movements and vocalizations called tics. Tourette syndrome affects more boys than girls, and the first symptoms usually occur between the ages of 5 and 10 years, generally in the head and neck area. (Source: nih.gov) SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimising side effects. The Phase IIb trial has commenced at Hannover Medical School, Hannover, Germany. The Phase IIb study is a randomised, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. In the trial, patients aged 18 to 65 will be randomised to receive either SCI-110 or placebo. The primary efficacy endpoint is the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared with baseline. According to the company, in the phase IIa study, SCI-110 demonstrated positive safety and efficacy results and showed an average tic reduction of 21% across all participants, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale. Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera Labs, commented: "The initiation of the German site marks an important step forward in our global development program for SCI-110". In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. SPRC has traded between $2.98 and $80.10 over the last year. The stock closed Tuesday's trade at $4.27. SPRC is currently up 1.41% at $4.33. For more biotech stock news visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags BioTech RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source -> Stocks mentioned SPRC More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.